Edmond DE Rothschild Holding S.A. Makes New Investment in Illumina, Inc. $ILMN

Key Points

• Edmond DE Rothschild Holding acquired 738,165 Illumina shares worth approximately $129.8 million, making the stock 1.7% of its portfolio and its 12th-largest holding. Institutional investors collectively own 89.42% of Illumina.
• Analyst sentiment remains mixed: Stifel raised its price target to $225 and Zacks upgraded the stock to “strong buy,” while Deutsche Bank downgraded it to “hold.” MarketBeat reports a consensus “hold” rating and an average target price of $188.40.
• Illumina exceeded quarterly expectations with adjusted EPS of $1.31 versus $1.23 expected and revenue of $1.16 billion, up 9.4% year over year. However, insiders sold 1.42 million shares worth about $256 million over the past three months.

Edmond DE Rothschild Holding S.A. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 738,165 shares of the life sciences company's stock, valued at approximately $129,792,000. Illumina comprises 1.7% of Edmond DE Rothschild Holding S.A.'s holdings, making the stock its 12th largest position. Edmond DE Rothschild Holding S.A. owned about 0.49% of Illumina at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Csenge Advisory Group acquired a new stake in shares of Illumina in the second quarter valued at about $1,112,000. West Family Investments Inc. acquired a new position in Illumina during the second quarter valued at approximately $219,000. NewEdge Wealth LLC bought a new position in Illumina in the second quarter valued at approximately $225,000. Monetta Financial Services Inc. bought a new position in Illumina in the second quarter valued at approximately $1,495,000. Finally, Eagle Health Investments LP acquired a new position in shares of Illumina during the 2nd quarter worth approximately $32,953,000. Institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

ILMN has been the topic of a number of analyst reports. Stifel Nicolaus upped their price objective on Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Weiss Ratings raised shares of Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, June 3rd. Sanford C. Bernstein restated a "market perform" rating and set a $215.00 target price on shares of Illumina in a report on Friday, July 31st. Zacks Research raised shares of Illumina from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 3rd. Finally, Deutsche Bank Aktiengesellschaft cut shares of Illumina to a "hold" rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $188.40.

Insider Activity at Illumina

In other news, insider Scott M. Davies sold 615 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the transaction, the insider directly owned 20,338 shares of the company's stock, valued at $4,067,600. This represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the firm's stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the sale, the chief accounting officer owned 14,946 shares of the company's stock, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,415,351 shares of company stock valued at $255,966,311. 2.90% of the stock is owned by company insiders.

Illumina Stock Performance

ILMN opened at $205.00 on Thursday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $207.00. The stock has a market cap of $30.95 billion, a price-to-earnings ratio of 38.25, a PEG ratio of 2.65 and a beta of 1.45. The business has a 50 day moving average of $185.90 and a 200-day moving average of $151.49. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source